AbbVie Earnings Reports

AbbVie delivered solid results in Q2 2025 with revenue growth driven by its immunology and neuroscience portfolios, despite ongoing declines in Humira sales and aesthetics.

AbbVie beat expectations in Q1 2025 with strong revenue growth led by Immunology and Neuroscience, despite challenges in the Aesthetics segment.

AbbVie reported a 5.6% increase in net revenues for Q4 2024, reaching $15.102 billion. The company's adjusted diluted EPS was $2.16, which includes an unfavorable impact of $0.88 related to acquired IPR&D and milestones expense. While some portfolios like Neuroscience and Oncology experienced growth, others like Aesthetics saw a decrease. The company provides 2025 adjusted diluted EPS guidance range of $12.12 to $12.32.

AbbVie reported a 3.8% increase in net revenues for the third quarter of 2024, reaching $14.460 billion. The company's adjusted diluted EPS was $3.00, a 1.7% increase. AbbVie also raised its full-year adjusted diluted EPS guidance and announced a dividend increase.

AbbVie reported a strong second quarter with net revenues of $14.462 billion, a 4.3% increase, and a GAAP EPS of $0.77. The company is raising its full-year adjusted diluted EPS guidance to $10.71 - $10.91.

AbbVie reported a 0.7% increase in net revenues to $12.310 billion for Q1 2024. GAAP diluted EPS was $0.77, while adjusted diluted EPS was $2.31, a decrease of 6.1 percent. The company has raised its full-year adjusted diluted EPS guidance.

AbbVie reported a decrease in net revenues and diluted EPS for the fourth quarter of 2023. Worldwide net revenues were $14.301 billion, a decrease of 5.4 percent. Diluted EPS was $0.46 on a GAAP basis, a decrease of 66.7 percent, while adjusted diluted EPS was $2.79, a decrease of 22.5 percent.

AbbVie reported Q3 2023 net revenues of $13.927 billion, a decrease of 6.0 percent. The company's adjusted diluted EPS was $2.95. AbbVie raised its full-year 2023 adjusted diluted EPS guidance and its floor EPS outlook for next year and increased its quarterly dividend.